The US Food and Drug Administration (FDA) has approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in ...
In Virginia, health statistics show more than 20,000 people depend on dialysis and just a few thousand fewer have had kidney ...
The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.
The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...
Investigators assessed frailty prevalence in a nationally representative US cohort and inpatient outcomes among kidney transplant recipients.
23h
John and his wife, Rachel Meadows, are sharing more about their search. The happy couple has twin 3-year-old boys, they say ...
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
March is National Kidney Month, and we're highlighting a York mother who gave her child the gift of life twice and says her ...
Discover why hydration is crucial for your brain, heart, and overall health. Learn how drinking water boosts energy, mood, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback